|1.||Falkenburg, J H Frederik: 20 articles (05/2015 - 01/2003)|
|2.||Dolstra, Harry: 13 articles (05/2015 - 10/2002)|
|3.||Goulmy, Els: 13 articles (01/2015 - 08/2002)|
|4.||Kester, Michel G D: 11 articles (05/2015 - 03/2003)|
|5.||Riddell, Stanley R: 10 articles (03/2011 - 08/2002)|
|6.||Fredrix, Hanny: 8 articles (05/2015 - 10/2002)|
|7.||Willemze, Roel: 8 articles (10/2009 - 03/2003)|
|8.||Korngold, Robert: 7 articles (06/2015 - 12/2003)|
|9.||van der Voort, Robbert: 7 articles (05/2015 - 03/2009)|
|10.||Heemskerk, Mirjam H M: 7 articles (05/2015 - 03/2003)|
05/01/2015 - "The therapeutic efficacy is based on donor-derived CD8(+) T cells that recognize minor histocompatibility antigens (MiHAs) expressed by patient's tumor cells. "
07/15/2009 - "New studies show that tumor-reactive T cells are directed against diverse tumor-specific targets as well as minor histocompatibility antigens."
03/19/2009 - "Targeting minor histocompatibility antigens (mHags) with hematopoiesis- and cancer-restricted expression, for example, HA-1, may allow boosting the antitumor effect of allogeneic SCT without risking severe GVHD. "
06/01/2008 - "Thus, it is crucial to identify minor histocompatibility antigens (mHags) only expressed in tumor cells but not GVHD target organs. "
05/01/2008 - "Here we review a number of approaches currently under investigation to specifically augment GVT effects, including the identification of minor histocompatibility antigens (mHA), adoptive immunotherapy with tumor-specific or mHA-specific cytotoxic T lymphocytes, vaccination of the donor or recipient to stimulate tumor-specific immunity, and adoptive transfer of natural killer cells. "
|2.||Graft vs Host Disease (Graft-Versus-Host Disease)
04/01/2005 - "Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission."
01/01/1988 - "A well-characterized murine model of graft-vs-host disease (GVHD) that develops in response to minor histocompatibility antigens was used to study the mechanism of an immunodeficiency syndrome that is associated with GVHD. "
08/01/1987 - "We have used a cell-wall-deficient mutant of Escherichia coli (E coli J5) to study the effect of active and passive immunization against bacterial endotoxin (ET) in a murine model of acute graft-versus-host disease (GVHD) induced by minor histocompatibility antigens. "
09/26/2013 - "Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease."
12/01/2009 - "However, graft-versus-host disease (GVHD), which is initiated by alloreactive donor T cells that recognize mismatched major and/or minor histocompatibility antigens and cause severe damage to hematopoietic and epithelial tissues, is a potentially lethal complication of allogeneic BMT. "
01/01/2015 - "This clinical complication has brought about a huge research effort that led to the development of leukemia-specific T-cell therapy aiming at the direct recognition of leukemia-specific rather than minor histocompatibility antigens. "
04/01/2014 - "CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT."
03/01/2011 - "Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia."
03/04/2003 - "Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia."
10/01/1999 - "Although currently minor histocompatibility antigens appear to be the most likely targets for DLI, several groups are focusing on the generation of leukemia-specific immunity. "
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
07/20/1999 - "We report that CD8(+) cytotoxic T lymphocyte (CTL) clones specific for minor histocompatibility antigens inhibit the engraftment of human acute myeloid leukemia cells in nonobese diabetic/SCID mice and demonstrate that this inhibition is mediated by direct CTL recognition of SCID leukemia-initiating cells. "
03/01/1995 - "A murine model for acute myeloid leukemia (mAML) was used to study graft-vs.-leukemia (GVL) effects on residual leukemic cells across both major (MHC) and minor histocompatibility antigens (mHA) barriers. "
09/01/1998 - "CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens."
03/01/1985 - "In previous studies it was found that BALB/c (H-2d) was more susceptible than (BALB/c X A)F1 (H-2d X H-2a) to a tumor bearing multiple mismatched minor histocompatibility antigens, the DBA/2 (H-2d) mastocytoma P815, and that this resistance was H-2 linked. "
10/01/1999 - "Mutant p53-expressing syngeneic, nontumor forming BALB/c 3T3 fibroblasts, tumor forming ras-transfected BALB/c 3T3 sarcomas, and DBA/2-derived P815 mastocytoma cells, which differ at the level of minor histocompatibility antigens, were used as cellular vaccines. "
|1.||16-iodo-3-methylhexadecanoic acid (MIHA)
|3.||Histocompatibility Antigens (Histocompatibility Antigen)
|5.||T-Cell Antigen Receptors (T-Cell Receptor)
|10.||Proteins (Proteins, Gene)
|4.||Stem Cell Transplantation
|5.||Bone Marrow Transplantation (Transplantation, Bone Marrow)